Chronic hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. In the last 5 years, treatment for HCV infection has experienced a marked development. In 2014, the use of ledipasvir/ sofosbuvir with or without concomitant weight-based ribavirin was approved with a very significant increase in the sustained virological response. However, new side effects have been associated. We report the first case of an HCV infected patient treated for 12 wk with the combination of sofosbuvir/ledipasvir plus ribavirin who developed a miliary tuberculosis (TB) infection while on therapy. The patient was a 65-year-old woman, who referred malaise, asthenia, hyporexia, 7 kg weight loss, productive cough, evening fever and night sweats, right after finishing the treatment. The chest computed tomography-scan revealed a superior mediastinal widening secondary to numerous lymphadenopathies with extensive necrosis and bilateral diffuse lung miliary pattern with little subsequent bilateral pleural effusion, highly suggestive of lymph node tuberculosis with lung miliary spread. A bronchoscopy was performed and bronchial suction showed more than 50 acid-alcohol resistant bacillus per line. A Mycobacterium tuberculosis DNA was detected in blood by polymerase chain reaction, which confirmed the diagnosis of miliary tuberculosis. Some cases of TB infection have been identified with α-interferon-based therapy and with the triple therapy of pegylated interferon, ribavirin and boceprevir or telaprevir. However, significant infection has not been reported with sofosbuvir/ledipasvir plus ribavirin.
Abstract
Chronic hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. In the last 5 years, treatment for HCV infection has experienced a marked development. In 2014, the use of ledipasvir/ sofosbuvir with or without concomitant weight-based ribavirin was approved with a very significant increase in the sustained virological response. However, new side effects have been associated. We report the first case of an HCV infected patient treated for 12 wk with the combination of sofosbuvir/ledipasvir plus ribavirin who developed a miliary tuberculosis (TB) infection while on therapy. The patient was a 65-year-old woman, who referred malaise, asthenia, hyporexia, 7 kg weight loss, productive cough, evening fever and night sweats, right after finishing the treatment. The chest computed tomography-scan revealed a superior mediastinal widening secondary to numerous lymphadenopathies with extensive necrosis and bilateral diffuse lung miliary pattern with little subsequent bilateral pleural effusion, highly suggestive of lymph node tuberculosis with lung miliary spread. A bronchoscopy was performed and bronchial suction showed more than 50 acid-alcohol resistant bacillus per line. A Mycobacterium tuberculosis DNA was detected in blood by polymerase chain reaction, which confirmed the diagnosis of miliary tuberculosis. Some cases of TB infection have been identified with α-interferon-based therapy and with the triple therapy of pegylated interferon, ribavirin and boceprevir or telaprevir. However, significant infection has not been reported with sofosbuvir/ledipasvir plus ribavirin.
INTRODUCTION
Affecting more than 160 million people and at an increa singly higher rate, hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. In the last 5 years, treatment for HCV infection has experienced a marked development, especially in the case of treatment for genotype 1. Previously, treatment was based on pegylated interferon and ribavirin for 48 wk, which achieved a sustained virological response (SVR) rate of 45% to 50%. In 2011, the first generation of protease inhibitorstelaprevir and boceprevirreached the market. The triple therapy with peginterferon, ribavirin and a protease inhibitor was then adopted as the standard of care, followed in 2013 by the approval of the second generation of protease inhibitor, simeprevir, and the polymerase inhibitor, sofosbuvir. In 2014, the use of ledipasvir/sofosbuvir was approved, as well as the use of ombitasvir/paritaprevir/ritonavir plus dasabuvir for the treatment of HCV genotype 1 infections with or without concomitant weightbased ribavirin. These changes have brought a very significant increase in the SVR, with rates rising above 90%. However, new side effects, such as decompensation of cirrhosis, liver toxicity and some infections, have been associated [1] . We report the first case of an HCVinfected patient treated for 12 wk with the combination of sofosbuvir/ ledipasvir plus ribavirin who developed a miliary tuber culosis infection while on therapy.
CASE REPORT
The patient was a 65yearold woman from Equatorial Guinea, who had been residing in Spain The checkup at the clinic one month later showed no symptoms or pathological signs on physical examination. The treatment was completed but in September, 2015, the patient complained about malaise, asthenia, hyporexia, 7 kg weight loss and dry cough. She referred that these symptoms had appeared one month before she was attended at the emergency unit. However, due to the clinical and hemodynamic stability, the patient was discharged with further outpatient control. In the next 2 wk, in early October, a more productive cough with white sputum, evening fever and night sweats were added to the previous symptoms and upon examination at the emergency unit again, the patient's temperature was 39 ℃, blood pressure was 131/94 mmHg, heart rate was 130 bpm with 98% oxygen saturation. She was conscious with no signs of neurologic impairment. Cardiac and pulmonary auscultation were normal, the abdomen was soft with a 3 cm hepatomegaly and a 2 cm splenomegaly without signs of ascites or abdominal pain, limbs showed no signs of edema and no cervical, axillary or inguinal adenopathies were found. The chest Xray showed a left hilar widening ( Figure 1 ) and the patient was admitted to the hospital for further studies. The blood culture was negative, as well as the malaria and leishmania tests. The sputum direct vision showed mixed microbiota with predominance of gram negative bacillus with no acidalcohol resistant bacillus (AARB) seen. Nevertheless, Mycobacterium tuberculosis showed up in the culture of the sputum after 10 d. Chest and abdomen CT scan revealed a superior mediastinal widening secondary to numerous lymphadenopathies with extensive necrosis, causing a displacement of the esophagus and trachea, and contiguous to these lympha denopathies, a left hilar mass displaying an air bubble communicated with the left bronchial three (Figure 2) , as well as a bilateral diffuse lung miliary pattern with little subsequent bilateral pleural effusion (Figure 3 ). These findings were highly suggestive of lymph node tuberculosis with lung miliary spread, being less likely to be attributed to a malignant left hilar mass. A flexible bronchoscopy was performed showing a bossing in the upper part of the trachea and mucosa thickening in both main bronchi with partial stenosis of the left upper lobule bronchi. The retrotracheal mass was biopsied, displaying acute inflammation in the pathological study with negative Zielh Neelsen test. However, in the bro nchial suction there were more than 50 AARB per line. A Mycobacterium tuberculosis DNA was detected in blood by RCP which confirmed the diagnosis of miliary tuberculosis. The first line treatment for tuberculosis with rifampin, isoniazid, pyrazinamide and ethambutol was initiated, presenting remission of the symptoms and a good tolerance with no signs of liver toxicity ( Figure 4 ).
DISCUSSION
Tuberculosis, caused by Mycobacterium tuberculosis, is a worldwide health problem, remaining as the leading cause of death from infectious diseases. It is estimated that 30% of the global population hosts TB in its latent form, which can be reactivated with the presence of several factors, such as aging, smoking, alcohol use, dia betes, chronic renal failure, cancer, a weakened immune system, glucocorticoids or tumor necrosis factorα in hibitors use. Furthermore, miliary tuberculosis form, has only been described in immunocompromised hosts, especially in patients with underlying Tcell deficiencies such as HIV infection. The classic presenting symptoms of pulmonary TB include persistent fever, weight loss, drenching night sweats, persistent cough (often with sputum production), and hemoptysis; whilst extra pulmonary TB can affect any organ with a wide variety of symptoms, and therefore requires a high index of clinical suspicion. Without treatment, TB has a mortality rate of 50% within 5 years. Various cell types and cytokines are crucial: T cells (CD4 + , CD8 + , and natural killer) and macrophages participate in protection against TB, and interferonα and tumor necrosis factorα (TNFα) are essential cytokines for the control of acute TB infection [3] . Two conditions might have contributed to the TB infection. On one hand, cirrhosis by itself is associated with lymphocyte and macrophage dysfunction and decreased production of interferonα and TNFα and it may be linked to a higher TB risk. A Taiwan study, showed that active TB incidence rates were significantly higher among cirrhotic patients compared with non cirrhotic patients, particularly those with alcoholism and HCV infection [4] . On the other hand, TB infection has been reported anecdotically in patients with HCV infection undergoing αinterferonbased therapy, usually as a reactivation of latent cases. As an example, 18 cases of TB were observed in patients under HCV treatment in Brazil [5] . Many studies have already shown that αinterferon inhibits type 1 immune response, which is characterized by IL2, interferonα and TNFα production, cytokines that restrain Mycobacterium tuberculosis. On the contrary, ribavirin is a guanosine analogue that has demonstrated to have an immunomodulatory effect, shifting a type 2 response to a type 1 in plaqueforming cells in vivo. When human Tlymphocytes are activated, ribavirin enhances a type 1 cytokine response producing in creased levels of IL2, interferonα and TNFα while suppressing the type 2 response with IL4, IL5 and IL10 [6] . Therefore, ribavirin stimulates the host adaptive immune response responsible for protection against TB infection and it may act as a protective factor; however, no studies have been specifically performed to prove it. Some other cases of TB infection have also been reported with the triple therapy of pegylated interferon, ribavirin and boceprevir or telaprevir, the first generation of protease inhibitors [1] . Ledipasvir and sofosbuvir are both DAAs. Sofosbuvir works as an inhibitor of the HCV NS5B RNAdependent RNA polymerase. Ledipasvir is an NS5A inhibitor and its exact mechanism of action is unknown, but one suggested mechanism is its inhibition of hyperphosphorylation of NS5A, which seems to be required for viral production. Ledipasvir/Sofosbuvir phase Ⅲ studies for HCV infection treatment showed that the most common adverse events reported by patients were fatigue, headache and nausea [7] . Addition of ribavirin to ledipasvir/sofosbuvir for HCV therapy for patients without cirrhosis or with compensated cirrhosis was associated with a greater incidence of common adverse effects, concomitant medication use and laboratory abnormalities such as anemia, increased levels of total bilirubin and lymphopenia; but rates of severe side effects and inter ruptions of treatment resulted similar, and no increased infection episodes were detected despite the reported decrease in lymphocytes [8] . In order to reduce the side effects of these drugs, advanced technologies are used during their development such as computeraided leading drug optimization [9] . Indeed, significant infection has not been reported with the new era of freeinterferon regiment treatment. This case is, to the best of our knowledge, the first case report of a miliary TB infection during HCV infection treat ment with sofosbuvir/ledipasvir plus ribavirin. Although the association with the DAAs has not been proven and it may be a coincidence that the two infections have occurred in a close time frame, several data should make clinicians wonder: The patient had diabetes and chronic liver disease as a risk factors for TB, nevertheless both were well controlled; she was asymptomatic and with no signs on physical examination neither before starting the treatment nor after one month of the beginning, which goes against the hypothesis that she may have reactivated TB prior to therapy and it has just presented late; moreover, the mechanisms underlying these drugs effects are currently unknown and further immunological studies should be performed in order to find out how the innate and adaptive immune responses are altered by the different treatment regimens [10] . We believe that the case we have reported is relevant to increase awareness of opportunistic infections, par ticularly TB infection due to its variety of symptoms which can be confused with those associated to the HCV infection or the antiviral treatment and the high mortality rate of TB infection without treatment. Considering the impaired immune system of cirrhotic patients and the fact that these DAAs arrived on the market slightly more than one year ago and no longterm side effects have been described, we consider that it is important to be conscious of the potential events that can be related with the HCV treatment. In addition, although the international guidelines for the management of HCV infection [11, 12] offer no recommendation regarding TB screening, we wonder whether it would be advisable to screen for opportunistic infections, via tuberculin skin test and/or interferon gamma releasing assays, prior to the introduction of HCV therapy.
COMMENTS

Case characteristics
A 65-year-old woman with history of diabetes mellitus type 2, chronic hepatitis C virus (HCV) infection and no current nor previous smoking habits and no underlying pulmonary disease or symptoms.
Clinical diagnosis
The patient presented with malaise, asthenia, hyporexia, 7 kg weight loss, productive cough with white sputum, evening fever and night sweats right after finishing the HCV treatment with sofosbuvir/ledipasvir plus ribavirin for 12 wk.
Differential diagnosis
Respiratory infection, side effects of HCV treatment.
Laboratory diagnosis
The 
Imaging diagnosis
The chest X-ray showed a left hilar widening. The chest computed tomography scan revealed a superior mediastinal widening secondary to numerous lymphadenopathies with extensive necrosis, causing a displacement of the esophagus and trachea, and contiguous to these lymphadenopathies, a left hilar mass displaying an air bubble communicated with the left bronchial three, as well as a bilateral diffuse lung miliary pattern with little subsequent bilateral pleural effusion.
Treatment
The first line treatment for tuberculosis with rifampin, isoniazid, pyrazinamide and ethambutol.
Related reports
Cases of tuberculosis infection have been identified with α-interferon-based therapy and the triple therapy with pegylated-interferon, ribavirin and boceprevir or telaprevir.
Experiences and lessons
This is the first case of a TB infection during treatment with sofosbuvir/ledipasvir plus ribavirin.
Peer-review
The manuscript is reasonably well written and is thought to have useful information for readers.
